Opens in a new tab

Enhertu Stumbles in Early Breast Cancer

Final TALENT results showed low pathological complete-response rates with neoadjuvant trastuzumab deruxtecan in HR-positive, HER2-low early breast cancer despite substantial radiological tumour shrinkage. A powerful metastatic drug has not automatically translated into a compelling curative strategy.

November 5, 2026
Editorial
High radiological response did not translate into high pathological complete response with neoadjuvant trastuzumab deruxtecan in HER2-low early breast cancer.[Sangiao Photography] / Shutterstock.com

IPM Take

This is why oncology needs sobering trials as much as positive ones. T-DXd has transformed metastatic HER2-low breast cancer, but curative-intent treatment has a different evidentiary bar. The field should resist assuming that moving an active drug earlier is automatically therapeutic progress.

Executive Summary

Final Phase II TALENT results in 132 patients with HR-positive, HER2-low stage II–III breast cancer showed pathological complete response rates of 7% with T-DXd alone, 3% with T-DXd plus anastrozole and 9% when T-DXd was followed by chemotherapy. Combined pCR/near-pCR rates remained 16–17%, despite objective radiological response rates of 62–72%. Three grade 2 drug-related interstitial lung disease events were reported, and one patient died in the T-DXd-alone arm.

Why it matters

  • Patients / advocates: Tumour shrinkage on imaging does not automatically mean eradication of invasive disease.
  • Clinicians: Metastatic efficacy cannot simply be extrapolated into the neoadjuvant setting.
  • Researchers / academia: HER2-low may not behave as the same therapeutic biomarker across disease stages.
  • Payers / regulators: Expensive ADCs entering curative treatment require a high evidence threshold.

The final TALENT results presented at ESMO 2026 are useful precisely because they resist one of oncology’s most common instincts: when a drug performs exceptionally well in metastatic disease, move it earlier and expect the benefit to become even greater. Trastuzumab deruxtecan has changed the treatment of metastatic HER2-low breast cancer, yet in this neoadjuvant HR-positive, HER2-low population, pathological complete response remained low across all three strategies despite much higher rates of radiological tumour shrinkage.

That gap between imaging response and pathological response deserves attention. In curative-intent treatment, shrinking a tumour before surgery can be valuable, but the therapeutic ambition is different from palliation or disease control in metastatic disease. Pathological eradication, surgical outcomes, recurrence risk and long-term survival matter greatly when patients are being exposed to an ADC with known risks, including interstitial lung disease. TALENT does not prove that T-DXd has no role in early breast cancer, but it clearly shows that metastatic reputation is not sufficient evidence for a neoadjuvant standard.

The study also raises a broader question about HER2-low as a biomarker. The category has been highly useful in metastatic disease, where it identifies patients who can benefit from antibody-drug conjugates despite not meeting conventional HER2-positive criteria. Whether the same expression threshold carries equivalent biological meaning in earlier disease is less certain. That uncertainty is exactly why trials such as TALENT matter: precision oncology has to keep revalidating both the treatment and the biomarker when the disease setting changes.

Source & Evidence